US6232320B1
(en)
|
1998-06-04 |
2001-05-15 |
Abbott Laboratories |
Cell adhesion-inhibiting antiinflammatory compounds
|
AU3127900A
(en)
*
|
1998-12-23 |
2000-07-31 |
Du Pont Pharmaceuticals Company |
Thrombin or factor xa inhibitors
|
WO2000053610A2
(en)
|
1999-03-09 |
2000-09-14 |
Pharmacia & Upjohn Company |
4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS
|
WO2000075145A1
(en)
*
|
1999-06-03 |
2000-12-14 |
Abbott Laboratories |
Cell adhesion-inhibiting antiinflammatory compounds
|
NZ516348A
(en)
*
|
1999-06-23 |
2003-06-30 |
Aventis Pharma Gmbh |
Substituted benzimidazole
|
US6689883B1
(en)
|
1999-09-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Substituted pyridines and pyridazines with angiogenesis inhibiting activity
|
JP2003522759A
(en)
*
|
2000-02-09 |
2003-07-29 |
ザ プロクター アンド ギャンブル カンパニー |
2-carboxamide-benzimidazoles
|
US7977333B2
(en)
|
2000-04-20 |
2011-07-12 |
Bayer Healthcare Llc |
Substituted pyridines and pyridazines with angiogenesis inhibiting activity
|
CN1638765A
(en)
|
2001-07-27 |
2005-07-13 |
柯里斯公司 |
Mediators of Hedgehog signaling pathways, compositions and uses related thereto
|
WO2003020728A1
(en)
|
2001-08-30 |
2003-03-13 |
Pharmacia & Upjohn Company |
4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
|
MXPA04001797A
(en)
|
2001-08-30 |
2004-07-08 |
Pharmacia & Upjhon Company |
4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS.
|
AR038117A1
(en)
|
2002-01-14 |
2004-12-29 |
Upjohn Co |
ANTIVIRAL AGENTS DERIVED FROM 4- OXO-4,7 -DIHYDROFIDE [2,3-B] PIRIDIN-5-CARBOXAMIDA
|
AR038294A1
(en)
|
2002-01-14 |
2005-01-12 |
Upjohn Co |
OXOTIENE (3,2-B) PYRIDINCARBOXAMIDS AS ANTIVIRAL AGENTS
|
AR038118A1
(en)
|
2002-01-14 |
2004-12-29 |
Upjohn Co |
COMPOUNDS DERIVED FROM ACID BENCINAMIDE 7-OXO-4,7-DIHIDROTIEN [2,3-B [PIRIDIN-6-CARBOXYLIC 3-REPLACED WHICH ARE USEFUL AS ANTIVIRAL
|
DE60335099D1
(en)
|
2002-05-06 |
2011-01-05 |
Vertex Pharma |
THIADIAZOLE OR OXADIAZOLE AND THEIR USE AS JAK PROTEIN KINASEINHIBITORS
|
AU2003246972A1
(en)
|
2002-08-06 |
2004-02-23 |
Astrazeneca Ab |
Condensed pyridines and pyrimidines with tie2 (tek) activity
|
IL154306A0
(en)
*
|
2003-02-05 |
2003-09-17 |
Rimonyx Pharmaceuticals Ltd |
Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
|
CN1950378A
(en)
*
|
2004-05-04 |
2007-04-18 |
霍夫曼-拉罗奇有限公司 |
Thienopyridazines as ikk inhibitors
|
WO2005105809A1
(en)
*
|
2004-05-04 |
2005-11-10 |
F. Hoffmann-La Roche Ag |
Thienopyridines as ikk inhibitors
|
EP1753428A4
(en)
*
|
2004-05-14 |
2010-09-15 |
Abbott Lab |
Kinase inhibitors as therapeutic agents
|
RU2007101509A
(en)
|
2004-06-17 |
2008-07-27 |
Уайт (Us) |
METHOD FOR PRODUCING HORMONE RECEPTOR ANTAGONISTS RELEASING GONADOTROPINE
|
BRPI0512261A
(en)
|
2004-06-17 |
2008-02-26 |
Wyeth Corp |
Gonadotropin-releasing hormone receptor antagonists
|
AU2005266803B2
(en)
|
2004-07-30 |
2011-10-27 |
Methylgene Inc. |
Inhibitors of VEGF receptor and HGF receptor signaling
|
JP2008508358A
(en)
|
2004-08-02 |
2008-03-21 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
Aryl-amino substituted pyrrolopyrimidine multikinase inhibitor compounds
|
GB0420722D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
KR20140008471A
(en)
*
|
2004-10-21 |
2014-01-21 |
다우 아그로사이언시즈 엘엘씨 |
Thieno-pyrimidine compounds having fungicidal activity
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
US7674822B2
(en)
|
2004-11-24 |
2010-03-09 |
Wyeth |
PTP1b inhibitors
|
AR054416A1
(en)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
|
US7582634B2
(en)
|
2005-02-18 |
2009-09-01 |
Wyeth |
7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7538113B2
(en)
|
2005-02-18 |
2009-05-26 |
Wyeth |
4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7534796B2
(en)
|
2005-02-18 |
2009-05-19 |
Wyeth |
Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7531542B2
(en)
|
2005-05-18 |
2009-05-12 |
Wyeth |
Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
|
CA2608726C
(en)
|
2005-05-20 |
2013-07-09 |
Methylgene Inc. |
Inhibitors of vegf receptor and hgf receptor signaling
|
BRPI0610322B8
(en)
|
2005-05-20 |
2021-05-25 |
Methylgene Inc |
vegf receptor and hgf receptor signaling inhibitors and pharmaceutical composition
|
US7582636B2
(en)
|
2005-05-26 |
2009-09-01 |
Wyeth |
Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
|
CN102127078A
(en)
|
2005-07-14 |
2011-07-20 |
安斯泰来制药株式会社 |
Heterocyclic janus kinase 3 inhibitors
|
EP1910358A2
(en)
|
2005-07-14 |
2008-04-16 |
Astellas Pharma Inc. |
Heterocyclic janus kinase 3 inhibitors
|
EP1917251B1
(en)
|
2005-08-21 |
2013-04-03 |
Abbott GmbH & Co. KG |
5-ring heteroaromatic compounds and their use as binding partners for 5-ht5 receptors
|
EP1926735A1
(en)
|
2005-09-22 |
2008-06-04 |
Incyte Corporation |
Tetracyclic inhibitors of janus kinases
|
LT2474545T
(en)
|
2005-12-13 |
2017-02-27 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
TWI417095B
(en)
|
2006-03-15 |
2013-12-01 |
Janssen Pharmaceuticals Inc |
1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
|
EP3421471B1
(en)
|
2006-04-25 |
2021-05-26 |
Astex Therapeutics Limited |
Purine and deazapurine derivatives as pharmaceutical compounds
|
US8227603B2
(en)
|
2006-08-01 |
2012-07-24 |
Cytokinetics, Inc. |
Modulating skeletal muscle
|
US8299248B2
(en)
|
2006-08-02 |
2012-10-30 |
Cytokinetics, Incorporated |
Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
|
ES2558517T3
(en)
|
2006-08-02 |
2016-02-04 |
Cytokinetics, Inc. |
Certain chemical entities, compositions and methods comprising imidazopyrimidines
|
WO2008079965A1
(en)
|
2006-12-22 |
2008-07-03 |
Incyte Corporation |
Substituted heterocycles as janus kinase inhibitors
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
EP2139478A4
(en)
|
2007-03-30 |
2010-05-05 |
Cytokinetics Inc |
Certain chemical entities, compositions and methods
|
CL2008001709A1
(en)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
|
CA2689663C
(en)
|
2007-06-13 |
2016-08-09 |
Incyte Corporation |
Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
PT2203439E
(en)
|
2007-09-14 |
2011-02-11 |
Ortho Mcneil Janssen Pharm |
1`,3`-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1`h-ý1, 4`¨bipyridinyl-2`-ones
|
WO2009033702A1
(en)
|
2007-09-14 |
2009-03-19 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc. |
1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
|
CN101861321B
(en)
|
2007-10-11 |
2013-02-06 |
阿斯利康(瑞典)有限公司 |
Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
|
BRPI0820544A2
(en)
|
2007-11-16 |
2015-06-16 |
Incyte Corp |
4-pyrazolyl-n-arylpyrimidin-2-amines and pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
US8217176B2
(en)
|
2008-02-26 |
2012-07-10 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic derivative and use thereof
|
BRPI0923670A2
(en)
|
2008-03-05 |
2013-07-30 |
Methylgene Inc |
protein tyrosine kinase activity inhibitors and their use, as well as a composition comprising them
|
RS55263B1
(en)
|
2008-03-11 |
2017-02-28 |
Incyte Holdings Corp |
Azetidine and cyclobutane derivatives as jak inhibitors
|
JP2011518836A
(en)
|
2008-04-24 |
2011-06-30 |
インサイト・コーポレイション |
Macrocycles and their use as kinase inhibitors
|
EP2344470B1
(en)
|
2008-09-02 |
2013-11-06 |
Janssen Pharmaceuticals, Inc. |
3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
|
CN102232074B
(en)
|
2008-11-28 |
2014-12-03 |
奥梅-杨森制药有限公司 |
Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
|
WO2010085597A1
(en)
|
2009-01-23 |
2010-07-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
CA2760741C
(en)
|
2009-05-12 |
2018-05-01 |
Addex Pharma S.A. |
1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
|
ES2409006T3
(en)
|
2009-05-12 |
2013-06-24 |
Janssen Pharmaceuticals Inc. |
1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
|
BRPI1012159B1
(en)
|
2009-05-22 |
2022-01-25 |
Incyte Holdings Corporation |
Compounds derived from n-(hetero)aryl-pyrrolidine of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors, compositions pharmaceuticals comprising said compounds and uses thereof
|
DK2432472T3
(en)
|
2009-05-22 |
2019-11-18 |
Incyte Holdings Corp |
3- [4- (7H-PYRROLO [2,3-D] PYRIMIDIN-4-YL) -1H-PYRAZOL-1-YL] OCTAN OR HEPTAN NITRIL AS JAK INHIBITORS
|
WO2010151317A1
(en)
|
2009-06-22 |
2010-12-29 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
CA2765678A1
(en)
|
2009-06-22 |
2010-12-29 |
Christopher Blackburn |
Substituted hydroxamic acids and uses thereof
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
CA2777114C
(en)
|
2009-10-09 |
2018-10-23 |
Incyte Corporation |
Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
KR20220015492A
(en)
|
2010-03-10 |
2022-02-08 |
인사이트 홀딩스 코포레이션 |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
PL2574168T3
(en)
|
2010-05-21 |
2016-10-31 |
|
Topical formulation for a jak inhibitor
|
CN102260270A
(en)
*
|
2010-05-28 |
2011-11-30 |
中国科学院上海药物研究所 |
N-(2-methylfuran[2,3-d]pyrimidine-4-yl)acrylamide, its preparation method and application
|
JP5852665B2
(en)
|
2010-11-08 |
2016-02-03 |
ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド |
1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor
|
CA2815002C
(en)
|
2010-11-08 |
2019-10-22 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
CN103298810B
(en)
|
2010-11-08 |
2016-03-16 |
杨森制药公司 |
The purposes of 1,2,4-triazolo [4,3-a] pyridine derivate and the positive allosteric modulators as MGLUR2 acceptor thereof
|
CA2818542A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
ES2536415T3
(en)
|
2010-11-19 |
2015-05-25 |
Incyte Corporation |
Pyrrolopyridines and heterocyclic substituted pyrrolopyrimidines as JAK inhibitors
|
US8778931B2
(en)
|
2010-12-22 |
2014-07-15 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
ES2547916T3
(en)
|
2011-02-18 |
2015-10-09 |
Novartis Pharma Ag |
MTOR / JAK inhibitor combination therapy
|
BR112013025410A2
(en)
|
2011-04-01 |
2016-12-20 |
Astrazeneca Ab |
therapeutic treatment
|
EP2721028B1
(en)
|
2011-06-20 |
2015-11-04 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
KR20140058543A
(en)
|
2011-07-08 |
2014-05-14 |
노파르티스 아게 |
Novel pyrrolo pyrimidine derivatives
|
WO2013010015A2
(en)
|
2011-07-13 |
2013-01-17 |
Cytokinetics, Inc. |
Combination als therapy
|
US9358229B2
(en)
|
2011-08-10 |
2016-06-07 |
Novartis Pharma Ag |
JAK PI3K/mTOR combination therapy
|
TW201313721A
(en)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
Cyclohexyl azetidine derivatives as JAK inhibitors
|
UA111854C2
(en)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
|
MX367640B
(en)
|
2011-11-30 |
2019-08-29 |
Astrazeneca Ab |
Combination treatment of cancer.
|
EP3141542B1
(en)
|
2011-12-28 |
2020-05-27 |
Global Blood Therapeutics, Inc. |
Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
|
ES2790358T3
(en)
|
2011-12-28 |
2020-10-27 |
Global Blood Therapeutics Inc |
Substituted Heteroaryl Aldehyde Compounds and Methods for Their Use in Increasing Tissue Oxygenation
|
AU2013204533B2
(en)
|
2012-04-17 |
2017-02-02 |
Astrazeneca Ab |
Crystalline forms
|
WO2013173720A1
(en)
|
2012-05-18 |
2013-11-21 |
Incyte Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
PE20200175A1
(en)
|
2012-11-15 |
2020-01-24 |
Incyte Holdings Corp |
SUSTAINED RELEASE RUXOLITINIB DOSAGE FORMS
|
UA120162C2
(en)
|
2013-03-06 |
2019-10-25 |
Інсайт Холдінгс Корпорейшн |
Processes and intermediates for making a jak inhibitor
|
US9604999B2
(en)
|
2013-03-15 |
2017-03-28 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
ES2852054T3
(en)
|
2013-03-15 |
2021-09-10 |
Global Blood Therapeutics Inc |
Compounds and their uses for modulation of hemoglobin
|
US10266551B2
(en)
|
2013-03-15 |
2019-04-23 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
US9458139B2
(en)
|
2013-03-15 |
2016-10-04 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
MX2015011448A
(en)
|
2013-03-15 |
2016-06-06 |
Global Blood Therapeutics Inc |
Compounds and uses thereof for the modulation of hemoglobin.
|
US20140274961A1
(en)
|
2013-03-15 |
2014-09-18 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
SG11201507453VA
(en)
|
2013-03-15 |
2015-10-29 |
Global Blood Therapeutics Inc |
Compounds and uses thereof for the modulation of hemoglobin
|
US10100043B2
(en)
|
2013-03-15 |
2018-10-16 |
Global Blood Therapeutics, Inc. |
Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
|
US8952171B2
(en)
|
2013-03-15 |
2015-02-10 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
US9422279B2
(en)
|
2013-03-15 |
2016-08-23 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
JO3368B1
(en)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
|
CA3155500A1
(en)
|
2013-08-07 |
2015-02-12 |
Incyte Corporation |
Sustained release dosage forms for a jak1 inhibitor
|
JO3367B1
(en)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
|
EA202092627A1
(en)
|
2013-11-18 |
2021-09-30 |
Глобал Блад Терапьютикс, Инк. |
COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
|
RU2693484C1
(en)
|
2013-11-22 |
2019-07-03 |
СиЭль БАЙОСАЕНСИЗ ЭлЭлСи |
Gastrin antagonists for treating and preventing osteoporosis
|
KR20200036063A
(en)
|
2014-01-21 |
2020-04-06 |
얀센 파마슈티카 엔.브이. |
Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
|
JP6629740B2
(en)
|
2014-01-21 |
2020-01-15 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Combinations comprising metabolic glutamatergic receptor subtype 2 positive allosteric modulators or orthosteric agonists and uses thereof
|
EP3868745A1
(en)
|
2014-02-07 |
2021-08-25 |
Global Blood Therapeutics, Inc. |
Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
MA41841A
(en)
|
2015-03-30 |
2018-02-06 |
Global Blood Therapeutics Inc |
ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES
|
WO2017096230A1
(en)
|
2015-12-04 |
2017-06-08 |
Global Blood Therapeutics, Inc. |
Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
|
TWI663160B
(en)
|
2016-05-12 |
2019-06-21 |
全球血液治療公司 |
Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
|
CN107513067A
(en)
|
2016-06-16 |
2017-12-26 |
北京赛林泰医药技术有限公司 |
Pyrrolopyrimidine compounds containing substituted cyclopenta
|
US10154992B2
(en)
*
|
2016-07-12 |
2018-12-18 |
The Regents Of The University Of California |
Compounds and methods for treating HIV infection
|
JOP20190024A1
(en)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
Substituted pyrrolizine compounds and uses thereof
|
TWI778983B
(en)
|
2016-10-12 |
2022-10-01 |
美商全球血液治療公司 |
Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
CN112105608B
(en)
|
2018-01-30 |
2023-07-14 |
因赛特公司 |
Process for the preparation of (1- (3-fluoro-2- (trifluoromethyl) isonicotinyl) piperidin-4-one
|
US10836769B2
(en)
|
2018-02-26 |
2020-11-17 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds and uses thereof
|
MX2020010322A
(en)
|
2018-03-30 |
2022-11-30 |
Incyte Corp |
Treatment of hidradenitis suppurativa using jak inhibitors.
|
EP3860975B1
(en)
|
2018-10-01 |
2023-10-18 |
Global Blood Therapeutics, Inc. |
Modulators of hemoglobin for the treatment of sickle cell disease
|
KR20210106506A
(en)
|
2018-12-21 |
2021-08-30 |
셀진 코포레이션 |
Thienopyridine inhibitor of RIPK2
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|